0000896622-23-000014.txt : 20230413 0000896622-23-000014.hdr.sgml : 20230413 20230413094155 ACCESSION NUMBER: 0000896622-23-000014 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 13 CONFORMED PERIOD OF REPORT: 20230413 ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20230413 DATE AS OF CHANGE: 20230413 FILER: COMPANY DATA: COMPANY CONFORMED NAME: APTARGROUP, INC. CENTRAL INDEX KEY: 0000896622 STANDARD INDUSTRIAL CLASSIFICATION: PLASTICS PRODUCTS, NEC [3089] IRS NUMBER: 363853103 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-11846 FILM NUMBER: 23817290 BUSINESS ADDRESS: STREET 1: 265 EXCHANGE DRIVE STREET 2: SUITE 301 CITY: CRYSTAL LAKE STATE: IL ZIP: 60014 BUSINESS PHONE: 8154770424 MAIL ADDRESS: STREET 1: 265 EXCHANGE DRIVE STREET 2: SUITE 301 CITY: CRYSTAL LAKE STATE: IL ZIP: 60014 FORMER COMPANY: FORMER CONFORMED NAME: APTARGROUP INC DATE OF NAME CHANGE: 19930129 8-K 1 atr-20230413.htm 8-K atr-20230413
0000896622FALSE00008966222023-04-132023-04-13

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
April 13, 2023
Date of Report (Date of earliest event reported)
AptarGroup, Inc.
(Exact name of registrant as specified in its charter)
Delaware001-1184636-3853103
(State or other jurisdiction of incorporation)(Commission File Number)(IRS Employer Identification No.)
265 Exchange Drive, Suite 301, Crystal Lake, Illinois 60014
(Address of principal executive offices)
Registrant’s telephone number, including area code: 815-477-0424.
N/A
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered
Common Stock, $.01 par valueATRNew York Stock Exchange
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company    ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.    ☐


Item 7.01      Regulation FD Disclosure.
AptarGroup, Inc. (“we,” “our,” “us,” “Aptar,” or the “Company,”) previously announced that, effective January 1, 2023, there was a realignment of two of our segments, allowing us to better serve our customers and positioning us for long-term profitable growth. During the years ended December 31, 2022 and 2021, our organizational structure consisted of three market-focused business segments: Pharma, Beauty + Home and Food + Beverage. Effective with this change, we continue to have three reporting segments and they are called Aptar Pharma, Aptar Beauty and Aptar Closures.
We combined all of our closures operations into a single segment - Aptar Closures. The Aptar Closures business serves multiple markets, including food, beverage, personal care, home care, beauty and healthcare. Closures that were developed in Beauty + Home moved to Aptar Closures together with the operations of legacy Food + Beverage. Aptar's food protection business and our elastomeric flow-control technology business continue to report through the Aptar Closures segment.
At the same time, we are simplifying and focusing our Beauty + Home segment to better leverage our complex spray and dispensing solutions for prestige and premium brands in the beauty and personal care markets. For many of our customers, personal care products are considered part of "beauty" and so we renamed this segment, simply, Aptar Beauty.
These changes are intended to help us increase our rate of innovation, broaden our market reach, streamline operations, increase effectiveness and raise capital efficiencies. Additionally, we intend to continue to focus on sustainability because leadership in sustainability remains a key differentiator across all of our segments. The Company's revised reporting segments are consistent with how the Company's chief operating decision maker is assessing operating performance and allocating capital resources following the realignment of its segment structure.
The Company is furnishing this Form 8-K to provide investors with unaudited historical segment operating and adjusted financial results consistent with its new reporting structure. The schedules in Exhibit 99.1 to this Current Report of Form 8-K provide unaudited operating and financial information on the basis of the Company’s new reporting segments for the previously-reported quarters in fiscal 2022 and the years ended December 31, 2022 and 2021.
The segment realignment discussed above and presented in Exhibit 99.1 hereto does not represent a restatement of previously issued financial statements, and does not change the Company’s previously reported consolidated financial results for any period, nor does it reflect any subsequent information or events, other than as required to reflect the change in reporting segments as described above. This information should be read in conjunction with our previously filed Form 10-K and Form 10-Qs. The information in Item 7.01 of this Form 8-K and the Exhibit 99.1 attached hereto shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), nor shall they be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended (the “Securities Act”), except as shall be expressly set forth by specific reference in such filing.
Presentation of Non-GAAP Information
Exhibit 99.1 attached hereto refers to certain non-GAAP financial measures, including adjusted EBITDA, which exclude the impact of business transformation charges (restructuring initiatives), acquisition-related costs, certain purchase accounting adjustments related to acquisitions and investments and net unrealized investment gains and losses related to observable market price changes on equity securities. Non-GAAP financial measures may not be comparable to similarly titled non-GAAP financial measures provided by other companies. Aptar’s management believes these non-GAAP financial measures provide useful information to our investors because they allow for a better period over period comparison of operating results by removing the impact of items that, in management’s view, do not reflect Aptar’s core operating performance. These non-GAAP financial measures also provide investors with certain information used by Aptar’s management when making financial and operational decisions. These non-GAAP financial measures should not be considered in isolation or as a substitute for GAAP financial results but should be read in conjunction with the unaudited condensed consolidated statements of income and other information included in Aptar’s previously filed Form 10-K and Form 10-Qs. A reconciliation of non-GAAP financial measures to the most directly comparable GAAP measures is included in the exhibit.


This Form 8-K contains forward-looking statements, including statements regarding our growth opportunities, strategic plans, market penetration, operational and capital efficiencies and sustainability goals. Words such as “expects,” “anticipates,” “believes,” “estimates,” “future,” “potential,” “continues” and other similar expressions or future or conditional verbs such as “will,” “should,” “would” and “could” are intended to identify such forward-looking statements. Forward-looking statements are made pursuant to the safe harbor provisions of Section 27A of the Securities Act and Section 21E of the Exchange Act and are based on our beliefs as well as assumptions made by and information currently available to us. Accordingly, our actual results or other events may differ materially from those expressed or implied in such forward-looking statements due to known or unknown risks and uncertainties that exist in our operations and business environment including, but not limited to: geopolitical conflicts worldwide including the invasion of Ukraine by the Russian military and the resulting indirect impact on demand from our customers selling their products into these countries, as well as rising input costs and certain supply chain disruptions; lower demand and asset utilization due to an economic recession either globally or in key markets we operate within; the impact of COVID-19 and its variants on our global supply chain and our global customers, employees and operations, which has elevated and will continue to elevate many of the risks and uncertainties discussed below; economic conditions worldwide, including inflationary conditions and potential deflationary conditions in other regions we rely on for growth; the execution of our restructuring initiatives; the availability of direct labor workers and the increase in direct labor costs, especially in North America; our ability to preserve organizational culture and maintain employee productivity in the work-from-home environment caused by the current pandemic; the availability of raw materials and components (particularly from sole sourced suppliers) as well as the financial viability of these suppliers; fluctuations in the cost of materials, components, transportation cost as a result of supply chain disruptions and labor shortages, and other input costs (particularly resin, metal, anodization costs and energy costs); significant fluctuations in foreign currency exchange rates or our effective tax rate; the impact of tax reform legislation, changes in tax rates and other tax-related events or transactions that could impact our effective tax rate; financial conditions of customers and suppliers; consolidations within our customer or supplier bases; changes in customer and/or consumer spending levels; loss of one or more key accounts; our ability to successfully implement facility expansions and new facility projects; our ability to offset inflationary impacts with cost containment, productivity initiatives and price increases; changes in capital availability or cost, including rising interest rates; volatility of global credit markets; our ability to identify potential new acquisitions and to successfully acquire and integrate such operations, including the successful integration of the businesses we have acquired, including contingent consideration valuation; our ability to build out acquired businesses and integrate the product/service offerings of the acquired entities into our existing product/service portfolio; direct or indirect consequences of acts of war, terrorism or social unrest; cybersecurity threats that could impact our networks and reporting systems; the impact of natural disasters and other weather-related occurrences; fiscal and monetary policies and other regulations; changes or difficulties in complying with government regulation; changing regulations or market conditions regarding environmental sustainability; work stoppages due to labor disputes; competition, including technological advances; our ability to protect and defend our intellectual property rights, as well as litigation involving intellectual property rights; the outcome of any legal proceeding that has been or may be instituted against us and others; our ability to meet future cash flow estimates to support our goodwill impairment testing; the demand for existing and new products; the success of our customers’ products, particularly in the pharmaceutical industry; our ability to manage worldwide customer launches of complex technical products, particularly in developing markets; difficulties in product development and uncertainties related to the timing or outcome of product development; significant product liability claims; and other risks associated with our operations. For additional information on these and other risks and uncertainties, please see our filings with the Securities and Exchange Commission, including the discussion under “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in our Form 10-K and Form 10-Qs. We undertake no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.
Item 9.01    Financial Statements and Exhibits.


SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
AptarGroup, Inc.
Date:  April 13, 2023
By:/s/ Robert W. Kuhn
Robert W. Kuhn
Executive Vice President and
Chief Financial Officer

 EX-99.1 2 atr-20221231xxrestatemente.htm EX-99.1 Document
Exhibit 99.1
AptarGroup, Inc.
Revenue by Segment & Geography (Unaudited)
($ In Thousands)
Revenue by segment and geography based on shipped from locations for each of the quarterly periods of 2022 is as follows:
For the Three Months Ended March 31, 2022
SegmentEuropeDomesticLatin
America		AsiaTotal
Aptar Pharma$211,007 $106,341 $7,855 $17,259 $342,462 
Aptar Beauty187,759 69,380 29,690 22,251 309,080 
Aptar Closures56,365 104,284 20,199 12,542 193,390 
Total$455,131 $280,005 $57,744 $52,052 $844,932 
For the Three Months Ended June 30, 2022
SegmentEuropeDomesticLatin
America		AsiaTotal
Aptar Pharma$209,118 $108,414 $6,339 $16,360 $340,231 
Aptar Beauty182,934 79,819 32,452 22,462 317,667 
Aptar Closures52,913 100,569 20,351 12,812 186,645 
Total$444,965 $288,802 $59,142 $51,634 $844,543 
For the Three Months Ended September 30, 2022
SegmentEuropeDomesticLatin
America		AsiaTotal
Aptar Pharma$212,751 $105,542 $6,309 $18,795 $343,397 
Aptar Beauty169,936 75,070 35,195 22,845 303,046 
Aptar Closures54,146 99,198 21,777 15,296 190,417 
Total$436,833 $279,810 $63,281 $56,936 $836,860 
For the Three Months Ended December 31, 2022
SegmentEuropeDomesticLatin
America		AsiaTotal
Aptar Pharma$203,571 $106,104 $6,572 $18,919 $335,166 
Aptar Beauty182,911 59,783 31,005 19,043 292,742 
Aptar Closures49,984 85,655 17,719 14,648 168,006 
Total$436,466 $251,542 $55,296 $52,610 $795,914 
Revenue by segment and geography based on shipped from locations for the years ended December 31, 2022 and 2021 is as follows:
For the Year Ended December 31, 2022
SegmentEuropeDomesticLatin
America		AsiaTotal
Aptar Pharma$836,447 $426,401 $27,075 $71,333 $1,361,256 
Aptar Beauty723,540 284,052 128,342 86,601 1,222,535 
Aptar Closures213,408 389,706 80,046 55,298 738,458 
Total$1,773,395 $1,100,159 $235,463 $213,232 $3,322,249 

1

For the Year Ended December 31, 2021
SegmentEuropeDomesticLatin
America		AsiaTotal
Aptar Pharma$830,552 $374,063 $21,482 $58,527 $1,284,624 
Aptar Beauty675,079 300,658 117,920 88,189 1,181,846 
Aptar Closures219,551 407,102 76,641 57,457 760,751 
Total$1,725,182 $1,081,823 $216,043 $204,173 $3,227,221 

2

AptarGroup, Inc.
Segment Information (Unaudited)
($ In Thousands)
Financial information regarding our reporting segments for each of the quarterly periods of 2022 is as follows:
Three Months EndedMarch 31June 30September 30December 31
Total Sales:
Aptar Pharma$346,672 $345,369 $345,079 $335,329 
Aptar Beauty315,368 323,794 308,353 298,503 
Aptar Closures196,068 189,166 192,706 170,115 
Total Sales$858,108 $858,329 $846,138 $803,947 
Less: Intersegment Sales:
Aptar Pharma$4,210 $5,138 $1,682 $163 
Aptar Beauty6,288 6,127 5,307 5,761 
Aptar Closures2,678 2,521 2,289 2,109 
Total Intersegment Sales$13,176 $13,786 $9,278 $8,033 
Net Sales:
Aptar Pharma$342,462 $340,231 $343,397 $335,166 
Aptar Beauty309,080 317,667 303,046 292,742 
Aptar Closures193,390 186,645 190,417 168,006 
Net Sales$844,932 $844,543 $836,860 $795,914 
Adjusted EBITDA (1):
Aptar Pharma$115,552 $111,006 $107,235 $107,829 
Aptar Beauty34,550 41,230 36,563 39,544 
Aptar Closures24,183 21,354 23,483 17,089 
Corporate & Other, unallocated(17,970)(13,663)(13,537)(17,760)
Acquisition-related costs (2)— — (231)— 
Restructuring Initiatives(291)(428)(2,270)(3,608)
Net unrealized investment (loss) gain (3)(2,091)(483)277 (1,026)
Depreciation and amortization(58,665)(58,552)(57,601)(58,888)
Interest Expense(8,930)(11,982)(9,756)(10,159)
Interest Income288 989 752 671 
Income before Income Taxes$86,626 $89,471 $84,915 $73,692 
(1)We evaluate performance of our reporting segments and allocate resources based upon Adjusted EBITDA. Adjusted EBITDA is defined as earnings before net interest, taxes, depreciation, amortization, unallocated corporate expenses, restructuring initiatives, acquisition-related costs, net unrealized investment gains and losses related to observable market price changes on equity securities and other special items.
(2)Acquisition-related costs include transaction costs and purchase accounting adjustments related to acquisitions and investments.
(3)Net unrealized investment (loss) gain represents the change in fair value of our investment in PureCycle Technologies (“PCT”).

3

Financial information regarding our reporting segments for the years ended December 31, 2022 and 2021 is as follows:
Years Ended December 31,20222021
Total Sales:
Aptar Pharma$1,372,449 $1,297,996 
Aptar Beauty1,246,018 1,204,312 
Aptar Closures748,055 768,497 
Total Sales$3,366,522 $3,270,805 
Less: Intersegment Sales:
Aptar Pharma$11,193 $13,372 
Aptar Beauty23,483 22,466 
Aptar Closures9,597 7,746 
Total Intersegment Sales$44,273 $43,584 
Net Sales:
Aptar Pharma$1,361,256 $1,284,624 
Aptar Beauty1,222,535 1,181,846 
Aptar Closures738,458 760,751 
Net Sales$3,322,249 $3,227,221 
Adjusted EBITDA (1):
Aptar Pharma$441,622 $425,714 
Aptar Beauty151,887 125,451 
Aptar Closures86,109 108,615 
Corporate & Other, unallocated(62,930)(52,314)
Acquisition-related costs (2)(231)(3,811)
Restructuring Initiatives(6,597)(23,240)
Net unrealized investment (loss) gain (3)(3,323)2,709 
Depreciation and amortization(233,706)(234,853)
Interest Expense(40,827)(30,284)
Interest Income2,700 3,668 
Income before Income Taxes$334,704 $321,655 
Capital Expenditures:
Aptar Pharma$164,396 $154,077 
Aptar Beauty74,203 87,442 
Aptar Closures44,223 47,225 
Corporate & Other29,491 29,686 
Transfer of Corporate Technology Expenditures (4)(1,886)(10,495)
Capital Expenditures$310,427 $307,935 
Total Assets:
Aptar Pharma$1,872,843 $1,833,512 
Aptar Beauty1,398,813 1,370,854 
Aptar Closures779,654 819,332 
Corporate & Other152,148 117,666 
Total Assets$4,203,458 $4,141,364 
(4)The transfer of corporate technology expenditures represents amounts of projects managed by corporate for the benefit of specific entities within each segment. Once the projects are complete, all related costs are allocated from corporate to and paid by the appropriate entity and the associated assets are then depreciated at the entity level.

4

AptarGroup, Inc.
Reconciliation of Adjusted EBIT and Adjusted EBITDA to Net Income (Unaudited)
($ In Thousands)
The reconciliation of Adjusted EBIT and Adjusted EBITDA to Net Income for each of the quarterly periods of 2022 is as follows:
Three Months Ended March 31, 2022
ConsolidatedAptar PharmaAptar BeautyAptar ClosuresCorporate & OtherNet Interest
Net Sales$844,932 $342,462 $309,080 $193,390 $— $— 
Reported net income$62,371 
Reported income taxes24,255 
Reported income before income taxes86,626 92,206 14,008 10,646 (21,592)(8,642)
Adjustments:
Restructuring initiatives291 — 111 180 — 
Net unrealized investment loss (1)
2,091 — — — 2,091 
Transaction costs related to acquisitions— — — — — 
Adjusted earnings before income taxes89,008 92,206 14,119 10,826 (19,501)(8,642)
Interest expense8,930 8,930 
Interest income(288)(288)
Adjusted earnings before net interest and taxes (Adjusted EBIT)97,650 92,206 14,119 10,826 (19,501)— 
Depreciation and amortization58,665 23,346 20,431 13,357 1,531 
Adjusted earnings before net interest, taxes, depreciation and amortization (Adjusted EBITDA)$156,315 $115,552 $34,550 $24,183 $(17,970)$— 
Adjusted EBITDA margins (Adjusted EBITDA / Reported Net Sales)18.5 %33.7 %11.2 %12.5 %

5

Three Months Ended June 30, 2022
ConsolidatedAptar PharmaAptar BeautyAptar ClosuresCorporate & OtherNet Interest
Net Sales$844,543 $340,231 $317,667 $186,645 $— $— 
Reported net income$63,613 
Reported income taxes25,858 
Reported income before income taxes89,471 87,445 20,459 8,188 (15,628)(10,993)
Adjustments:
Restructuring initiatives428 — 423 5 — 
Net unrealized investment loss (1)
483 — — — 483 
Transaction costs related to acquisitions— — — — — 
Adjusted earnings before income taxes90,382 87,445 20,882 8,193 (15,145)(10,993)
Interest expense11,982 11,982 
Interest income(989)(989)
Adjusted earnings before net interest and taxes (Adjusted EBIT)101,375 87,445 20,882 8,193 (15,145)— 
Depreciation and amortization58,552 23,561 20,348 13,161 1,482 
Adjusted earnings before net interest, taxes, depreciation and amortization (Adjusted EBITDA)$159,927 $111,006 $41,230 $21,354 $(13,663)$— 
Adjusted EBITDA margins (Adjusted EBITDA / Reported Net Sales)18.9 %32.6 %13.0 %11.4 %

6

Three Months Ended September 30, 2022
ConsolidatedAptar PharmaAptar BeautyAptar ClosuresCorporate & OtherNet Interest
Net Sales$836,860 $343,397 $303,046 $190,417 $— $— 
Reported net income$54,177 
Reported income taxes30,738 
Reported income before income taxes84,915 83,571 14,729 10,460 (14,841)(9,004)
Adjustments:
Restructuring initiatives2,270 — 2,240 30 — 
Net unrealized investment gain (1)
(277)— — — (277)
Transaction costs related to acquisitions231 231 — — — 
Adjusted earnings before income taxes87,139 83,802 16,969 10,490 (15,118)(9,004)
Interest expense9,756 9,756 
Interest income(752)(752)
Adjusted earnings before net interest and taxes (Adjusted EBIT)96,143 83,802 16,969 10,490 (15,118)— 
Depreciation and amortization57,601 23,433 19,594 12,993 1,581 
Adjusted earnings before net interest, taxes, depreciation and amortization (Adjusted EBITDA)$153,744 $107,235 $36,563 $23,483 $(13,537)$— 
Adjusted EBITDA margins (Adjusted EBITDA / Reported Net Sales)18.4 %31.2 %12.1 %12.3 %

7

Three Months Ended December 31, 2022
ConsolidatedAptar PharmaAptar BeautyAptar ClosuresCorporate & OtherNet Interest
Net Sales$795,914 $335,166 $292,742 $168,006 $— $— 
Reported net income$59,394 
Reported income taxes14,298 
Reported income before income taxes73,692 83,773 16,654 2,891 (20,138)(9,488)
Adjustments:
Restructuring initiatives3,608 — 2,765 843 — 
Net unrealized investment loss (1)
1,026 — — — 1,026 
Transaction costs related to acquisitions— — — — — 
Adjusted earnings before income taxes78,326 83,773 19,419 3,734 (19,112)(9,488)
Interest expense10,159 10,159 
Interest income(671)(671)
Adjusted earnings before net interest and taxes (Adjusted EBIT)87,814 83,773 19,419 3,734 (19,112)— 
Depreciation and amortization58,888 24,056 20,125 13,355 1,352 
Adjusted earnings before net interest, taxes, depreciation and amortization (Adjusted EBITDA)$146,702 $107,829 $39,544 $17,089 $(17,760)$— 
Adjusted EBITDA margins (Adjusted EBITDA / Reported Net Sales)18.4 %32.2 %13.5 %10.2 %


8

The reconciliation of Adjusted EBIT and Adjusted EBITDA to Net Income for the years ended December 31, 2022 and 2021 is as follows:
Year Ended December 31, 2022
ConsolidatedAptar PharmaAptar BeautyAptar ClosuresCorporate & OtherNet Interest
Net Sales$3,322,249 $1,361,256 $1,222,535 $738,458 $— $— 
Reported net income$239,555 
Reported income taxes95,149 
Reported income before income taxes334,704 346,995 65,850 32,185 (72,199)(38,127)
Adjustments:
Restructuring initiatives6,597 — 5,539 1,058 — 
Net unrealized investment loss (1)
3,323 — — — 3,323 
Transaction costs related to acquisitions231 231 — — — 
Adjusted earnings before income taxes344,855 347,226 71,389 33,243 (68,876)(38,127)
Interest expense40,827 40,827 
Interest income(2,700)(2,700)
Adjusted earnings before net interest and taxes (Adjusted EBIT)382,982 347,226 71,389 33,243 (68,876)— 
Depreciation and amortization233,706 94,396 80,498 52,866 5,946 
Adjusted earnings before net interest, taxes, depreciation and amortization (Adjusted EBITDA)$616,688 $441,622 $151,887 $86,109 $(62,930)$— 
Adjusted EBITDA margins (Adjusted EBITDA / Reported Net Sales)18.6 %32.4 %12.4 %11.7 %

9

Year Ended December 31, 2021
ConsolidatedAptar PharmaAptar BeautyAptar ClosuresCorporate & OtherNet Interest
Net Sales$3,227,221 $1,284,624 $1,181,846 $760,751 $— $— 
Reported net income$243,638 
Reported income taxes78,017 
Reported income before income taxes321,655 331,317 33,923 52,358 (69,327)(26,616)
Adjustments:
Restructuring initiatives23,240 76 8,149 2,702 12,313 
Net unrealized investment gain (1)
(2,709)— — — (2,709)
Transaction costs related to acquisitions3,811 3,811 — — — 
Adjusted earnings before income taxes345,997 335,204 42,072 55,060 (59,723)(26,616)
Interest expense30,284 30,284 
Interest income(3,668)(3,668)
Adjusted earnings before net interest and taxes (Adjusted EBIT)372,613 335,204 42,072 55,060 (59,723)— 
Depreciation and amortization234,853 90,510 83,379 53,555 7,409 — 
Adjusted earnings before net interest, taxes, depreciation and amortization (Adjusted EBITDA)$607,466 $425,714 $125,451 $108,615 $(52,314)$— 
Adjusted EBITDA margins (Adjusted EBITDA / Reported Net Sales)18.8 %33.1 %10.6 %14.3 %
(1)Net unrealized investment gain (loss) represents the change in fair value of our investment in PCT.

10
 EX-101.SCH 3 atr-20230413.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 atr-20230413_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Entity Central Index Key Entity Central Index Key Entity Address, Address Line Two Entity Address, Address Line Two Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Trading Symbol Trading Symbol Entity File Number Entity File Number Pre-commencement Issuer Tender Offer Pre-commencement Issuer Tender Offer Soliciting Material Soliciting Material Entity Address, City or Town Entity Address, City or Town Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Local Phone Number Local Phone Number Entity Address, Postal Zip Code Entity Address, Postal Zip Code Written Communications Written Communications City Area Code City Area Code Cover [Abstract] Title of 12(b) Security Title of 12(b) Security Document Type Document Type Amendment Flag Amendment Flag Security Exchange Name Security Exchange Name Entity Registrant Name Entity Registrant Name Entity Emerging Growth Company Entity Emerging Growth Company Entity Address, State or Province Entity Address, State or Province Document Period End Date Document Period End Date Pre-commencement Tender Offer Pre-commencement Tender Offer EX-101.PRE 5 atr-20230413_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 6 R1.htm IDEA: XBRL DOCUMENT v3.23.1
Cover
Apr. 13, 2023
Cover [Abstract]  
Document Type 8-K
Document Period End Date Apr. 13, 2023
Entity Registrant Name AptarGroup, Inc.
Entity Incorporation, State or Country Code DE
Entity File Number 001-11846
Entity Tax Identification Number 36-3853103
Entity Address, Address Line One 265 Exchange Drive
Entity Address, Address Line Two Suite 301
Entity Address, City or Town Crystal Lake
Entity Address, State or Province IL
Entity Address, Postal Zip Code 60014
City Area Code 815
Local Phone Number 477-0424
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, $.01 par value
Trading Symbol ATR
Security Exchange Name NYSE
Entity Emerging Growth Company false
Entity Central Index Key 0000896622
Amendment Flag false
XML 7 atr-20230413_htm.xml IDEA: XBRL DOCUMENT 0000896622 2023-04-13 2023-04-13 0000896622 false 8-K 2023-04-13 AptarGroup, Inc. DE 001-11846 36-3853103 265 Exchange Drive Suite 301 Crystal Lake IL 60014 815 477-0424 false false false false Common Stock, $.01 par value ATR NYSE false 2023-04-13 EXCEL 8 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 9 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 10 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 11 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.1 html 1 23 1 false 0 0 false 0 false false R1.htm 0000001 - Document - Cover Sheet http://www.aptargroup.com/role/Cover Cover Cover 1 false false All Reports Book All Reports atr-20230413.htm atr-20221231xxrestatemente.htm atr-20230413.xsd atr-20230413_lab.xml atr-20230413_pre.xml http://xbrl.sec.gov/dei/2022 true false JSON 13 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "atr-20230413.htm": { "axisCustom": 0, "axisStandard": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2022": 24 }, "contextCount": 1, "dts": { "inline": { "local": [ "atr-20230413.htm" ] }, "labelLink": { "local": [ "atr-20230413_lab.xml" ] }, "presentationLink": { "local": [ "atr-20230413_pre.xml" ] }, "schema": { "local": [ "atr-20230413.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd" ] } }, "elementCount": 24, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2022": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 23, "memberCustom": 0, "memberStandard": 0, "nsprefix": "atr", "nsuri": "http://www.aptargroup.com/20230413", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "atr-20230413.htm", "contextRef": "i17888368324b425e831db2edc678665a_D20230413-20230413", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "0000001 - Document - Cover", "menuCat": "Cover", "order": "1", "role": "http://www.aptargroup.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "atr-20230413.htm", "contextRef": "i17888368324b425e831db2edc678665a_D20230413-20230413", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.aptargroup.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.aptargroup.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2022", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.aptargroup.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.aptargroup.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.aptargroup.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two", "terseLabel": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.aptargroup.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.aptargroup.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.aptargroup.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.aptargroup.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.aptargroup.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.aptargroup.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.aptargroup.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.aptargroup.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.aptargroup.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.aptargroup.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.aptargroup.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer", "terseLabel": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.aptargroup.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer", "terseLabel": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.aptargroup.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.aptargroup.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.aptargroup.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.aptargroup.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.aptargroup.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.aptargroup.com/role/Cover" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425", "role": "http://www.xbrl.org/2003/role/presentationRef" } }, "version": "2.2" } ZIP 14 0000896622-23-000014-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000896622-23-000014-xbrl.zip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